Company Overview and News

0
Despite The Ongoing Bull Market In Copper, Amerigo Resources Is Still Deeply Undervalued

2018-06-14 seekingalpha
As a result, next year the company is expected to increase its copper production to 85 - 90 million pounds (62.5 million in 2017).
ARREF ARG

0
Amerigo Resources' (ARREF) CEO Robert Henderson on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Amerigo Resources Ltd. (OTCQX:ARREF) Q1 2018 Results Earnings Conference Call May 10, 2018 2:00 PM ET
ARREF ARG

0
Amerigo Announces Q1-2018 Financial Results

2018-05-09 globenewswire
VANCOUVER, British Columbia, May 09, 2018 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX:ARG) (“Amerigo” or the “Company”) announced today financial results for the three months ended March 31, 2018. The Company posted revenue of $33.9 million and net income of $1.2 million. Cash of $5.9 million was generated from operations before working capital changes. At March 31, 2018, cash balance was $29.9 million.
ARG ARREF

0
Amerigo Announces Results of AGM

2018-05-08 globenewswire
VANCOUVER, British Columbia , May 08, 2018 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX:ARG) ("Amerigo" or the "Company") announces the results of voting at its 2018 Annual General Meeting of Shareholders (“AGM”) held on May 7, 2018 in Vancouver British Columbia.
ARG ARREF

0
Amerigo Announces Q1-2018 Production Results

2018-04-16 globenewswire
VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. ("Amerigo" or the "Company") (TSX:ARG) announced today production results for Q1-2018 from Minera Valle Central ("MVC"), the Company’s 100% owned operation located near Rancagua, Chile.
ARG ARREF

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:ARG / Amerigo Resources Ltd. on message board site Silicon Investor.

Speculating in Takeover Targets Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit
Shipping - Oil u0026 Gas Tankers, Dry cargo, LNG WELLS FARGO
Plinking,Target-Shooting and other forms of Mayhem SRNE at $1.90 -- Target Price Issued at $20!
TGT: Target Corporation Amsterdam - Largest Adult Theme Park
Shopping For The Ultimate Bargains Your 5 largest stock positions